Cargando…
The Onchocerca volvulus Cysteine Proteinase Inhibitor, Ov-CPI-2, Is a Target of Protective Antibody Response That Increases with Age
BACKGROUND: Despite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive. Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity in onch...
Autores principales: | Cho-Ngwa, Fidelis, Liu, Jing, Lustigman, Sara |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927424/ https://www.ncbi.nlm.nih.gov/pubmed/20808763 http://dx.doi.org/10.1371/journal.pntd.0000800 |
Ejemplares similares
-
Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans
por: George, Parakkal Jovvian, et al.
Publicado: (2019) -
The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice
por: Hess, Jessica A., et al.
Publicado: (2016) -
Nodding syndrome (NS) and Onchocerca Volvulus (OV) in Northern Uganda
por: Lagoro, David Kitara, et al.
Publicado: (2017) -
Prediction and validation of the structural features of Ov58GPCR, an immunogenic determinant of Onchocerca volvulus
por: Shey, Robert Adamu, et al.
Publicado: (2018) -
Patent infections with soil-transmitted helminths and Schistosoma mansoni are not associated with increased prevalence of antibodies to the Onchocerca volvulus peptide epitopes OvMP-1 and OvMP-23
por: Vlaminck, Johnny, et al.
Publicado: (2019)